A clinical briefing on the Insulin Lispro shortage in 2026. Coverage of supply timelines, prescribing implications, alternatives, and tools for providers.
Insulin Lispro remains one of the most widely prescribed rapid-acting insulin analogs in the United States, with millions of patients depending on it for prandial glucose control. Over the past two years, supply disruptions have required prescribers to navigate formulary shifts, counsel patients on product substitutions, and, in some cases, transition patients to alternative rapid-acting insulins.
This article provides an up-to-date overview of the Insulin Lispro shortage situation, its prescribing implications, and practical tools to help you support your patients in 2026.
In March 2023, Eli Lilly announced a 70% reduction in the list price of Humalog and introduced an authorized generic Insulin Lispro vial at a list price of just $25. The Lilly Insulin Value Program was expanded to cap patient out-of-pocket costs at $35/month regardless of insurance status. While transformative for patient access, these changes triggered a significant demand surge that strained manufacturing and distribution capacity.
By mid-2024, Eli Lilly began reporting supply limitations for certain Insulin Lispro products. Increased demand, coupled with manufacturing line transitions, resulted in intermittent shortages of specific NDCs. The ASHP added several Insulin Lispro formulations to its drug shortage database.
In October 2025, Lilly officially discontinued the 3 mL vial presentations of Insulin Lispro as a business decision. Concurrently, Sanofi reported supply constraints for Admelog/Insulin Lispro Sanofi affecting European and EEA markets beginning Q1 2026, signaling ongoing global manufacturing capacity challenges for rapid-acting insulin analogs.
The supply picture has improved for most common presentations. The 10 mL vials and KwikPen products are generally available, though regional variations persist. Specific NDCs tracked by ASHP may remain in limited supply. Admelog availability is inconsistent in some markets.
The interplay between payer formularies and product availability creates a complex landscape for prescribers. Key considerations include:
When transitioning patients between Insulin Lispro formulations or brands:
If a patient's formulary-preferred insulin is unavailable due to shortage, most payers have expedited exception processes. Document the shortage as the clinical rationale for the formulary exception. ASHP shortage notices and FDA shortage listings serve as supporting evidence.
| Product | Status (March 2026) | Notes |
|---|---|---|
| Insulin Lispro 100 units/mL, 10 mL vial (generic) | Generally available | List price $25/vial |
| Insulin Lispro KwikPen 100 units/mL, 5-pack | Generally available | Some NDCs intermittently limited |
| Insulin Lispro 3 mL vial | Discontinued | Discontinued October 2025 |
| Humalog 100 units/mL, 10 mL vial | Available | 70% price reduction effective |
| Humalog KwikPen 100 units/mL | Available | |
| Humalog U-200 KwikPen | Available | |
| Admelog 100 units/mL | Intermittent | EU/EEA shortages reported Q1 2026 |
| Lyumjev 100 units/mL | Available | Covered by Lilly Insulin Value Program |
For patients experiencing financial barriers:
Medfinder for Providers enables clinicians and care teams to check real-time pharmacy availability of Insulin Lispro and other medications. This can be particularly valuable during shortage periods, allowing you to direct patients to pharmacies that currently have stock rather than sending them on a frustrating search.
Consider sharing these resources with patients who are affected by the shortage:
The insulin supply landscape continues to evolve. Key developments to monitor in 2026 include:
The Insulin Lispro shortage has required prescribers to be more proactive about supply monitoring, formulary navigation, and patient counseling. While the situation has improved materially since 2024, complete resolution remains a work in progress — particularly for less common formulations and in underserved regions.
Leveraging tools like Medfinder for Providers, staying current on ASHP shortage updates, and maintaining familiarity with therapeutic alternatives positions your practice to minimize disruption for the patients who depend on this essential medication.
For additional provider-focused guidance on helping patients navigate insulin access, see our companion article: How to help your patients find Insulin Lispro in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
